Although TLR7 can activate both NF-κB and IRFs, in turn inducing inflammatory and antiviral responses, during SARS-CoV-2 lung infection, TLR7 has been shown to mainly activate the NF-κB pathway contributing to the overt production of pro-inflammatory cytokines in patients with severe COVID-19 [32,34]. This evidence concerns the gene NFKB1 and COVID-19.